Literature DB >> 8852472

In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.

R Baradaran-Dilmaghani1, G Stanek.   

Abstract

Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) were evaluated of the antimicrobial chemotherapeutics amoxicillin, azithromycin, cefotaxime, ceftriaxone, doxycycline, penicillin G sodium, roxithromycin, and trimethoprim-sulfamethoxazole for 30 Borrelia strains from various sources (skin, cerebrospinal fluid, ticks). Of these strains 29 were Lyme disease agents of the species Borrelia afzelii (n = 12), Borrelia burgdorferi sensu stricto (n = 4), Borrelia garinii (n = 13), and one was the relapsing fever strain Borrelia turicatae (n = 1). Tests were performed in microtiter plates by broth dilution. MIC was determined after 72 hours of incubation by comparing growth control with the antibiotic dilutions by means of dark field microscopy. Strains tested were susceptible against amoxicillin, azithromycin, cefotaxime, ceftriaxone, doxycycline, and penicillin G sodium, partly susceptible to roxithromycin, and resistant to trimethoprim-sulfamethoxazole. No statistically significant differences in MIC and MBC were seen among the different antibiotics with the various Borrelia species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852472     DOI: 10.1007/bf01780660

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

2.  High-dose penicillin therapy in meningopolyneuritis Garin-Bujadoux-Bannwarth. Clinical and cerebrospinal fluid data.

Authors:  W Kristoferitsch; U Baumhackl; E Sluga; G Stanek; K Zeiler
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

3.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

4.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors:  K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

5.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07

6.  Antibiotic therapy in early erythema migrans disease and related disorders.

Authors:  K Weber; U Neubert; R Thurmayr
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-02

7.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

8.  Successful parenteral penicillin therapy of established Lyme arthritis.

Authors:  A C Steere; J Green; R T Schoen; E Taylor; G J Hutchinson; D W Rahn; S E Malawista
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

9.  European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

Authors:  V Preac-Mursic; B Wilske; G Schierz
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-12

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
  10 in total
  14 in total

1.  In Vitro Susceptibility of Treponema pallidum subsp. pallidum to Doxycycline.

Authors:  Diane G Edmondson; Gary P Wormser; Steven J Norris
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.

Authors:  Martin Sicklinger; Ralf Wienecke; Uwe Neubert
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Pharmacokinetic analysis of oral doxycycline in rhesus macaques.

Authors:  Monica E Embers; Nicole R Hasenkampf; Dale G Embers; Lara A Doyle
Journal:  J Med Primatol       Date:  2012-12-20       Impact factor: 0.667

6.  Distribution of Borrelia burgdorferi sensu lato genomic groups in Europe, a review.

Authors:  Z Hubálek; J Halouzka
Journal:  Eur J Epidemiol       Date:  1997-12       Impact factor: 8.082

Review 7.  Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature.

Authors:  Nathalie D van Burgel; Mayke Oosterloo; Frank P Kroon; Alje P van Dam
Journal:  BMC Neurol       Date:  2010-11-30       Impact factor: 2.474

8.  Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability.

Authors:  Radha Iyer; Priyanka Mukherjee; Kemeng Wang; Joshua Simons; Gary P Wormser; Ira Schwartz
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

9.  Persister Development by Borrelia burgdorferi Populations In Vitro.

Authors:  John R Caskey; Monica E Embers
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

10.  In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.

Authors:  Joris Koetsveld; Ronald O P Draga; Alex Wagemakers; Annemijn Manger; Anneke Oei; Caroline E Visser; Joppe W Hovius
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.